Gilead Sciences'(GILD) CEO Gregg Alton on Q4 2018 Results - Earnings Call Transcript

Feb. 04, 2019 8:18 PM ETGilead Sciences, Inc. (GILD)10 Comments
SA Transcripts profile picture
SA Transcripts

Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2018 Earnings Conference Call February 4, 2019 4:30 PM ET

Company Participants

Sung Lee – Vice President of Investor Relations

Robin Washington – Executive Vice President and Chief Financial Officer

Laura Hamill – Executive Vice President, Worldwide Commercial Operations

John McHutchison – Chief Scientific Officer and Head of Research and Development

Gregg Alton – Interim Chief Executive Officer and Chief Patient Officer

Conference Call Participants

Geoff Meacham – Barclays

Michael Yee – Jefferies

Brian Abrahams – RBC Capital Markets

Geoffrey Porges – Leerink

Matthew Harrison – Morgan Stanley

Robyn Karnauskas – Citi

Alethia Young – Cantor Fitzgerald

Umer Raffat – Evercore ISI

Cory Kasimov – JPMorgan

Phil Nadeau – Cowen and Company

Salim Syed – Mizuho Securities

Terence Flynn – Goldman Sachs

Ying Huang – Bank of America Merrill Lynch

Carter Gould – UBS


Ladies and gentlemen, thank you for standing by, and welcome to Gilead Sciences Fourth Quarter 2018 Earnings Conference Call. My name is Jonathan. I will be your conference operator today. At this time, all participants are in a listen-only mode. And as a reminder, this conference call is being recorded.

I would now like to turn the call over to Sung Lee, Vice President of Investor Relations. Please go ahead.

Sung Lee

Thank you, Jonathan, and good afternoon, everyone. Just after market closed today, we issued a press release with earnings results for the fourth quarter 2018. The press release and detailed slides are available on the Investor Relations section of the Gilead website.

The speakers on today’s call will be: Robin Washington, Executive Vice President and Chief Financial Officer; Laura Hamill, Executive Vice President, Worldwide Commercial Operations; and John McHutchison, Chief Scientific Officer and Head of Research and Development; also in the room is Gregg Alton, Interim CEO and Chief Patient Officer.

Recommended For You

Comments (10)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.